Loading, Please Wait...
- Commenced Phase 3 Trial of APL-2 in Paroxysmal Nocturnal Hemoglobinuria (PNH); APL-2 in Geographic Atrophy (GA) Remains On Track to Advance into Phase 3 in 2H18 -
- Cash Position of $253.8 Million at Quarter-End -
CRESTWOOD, Ky. and CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced its second quarter 2018 financial results and business highlights.
“The second quarter of 2018 was marked by significant clinical progress of APL-2, particularly for the potential treatment of PNH,” said Cedric Francois, MD, PhD, founder and chief executive officer of Apellis. “At our R&D Day, we announced the earlier than anticipated enrollment of the first patient in the Phase 3 PEGASUS trial of APL-2 head-to-head with Soliris, and additional patient data from the ongoing PADDOCK and PHAROAH Phase 1b trials of APL-2 in patients with PNH. We also reported initial data from the Phase 2 proof-of-concept (POC) monotherapy trial of APL-2 in autoimmune hemolytic anemia (AIHA). In the second half of 2018, we plan to continue to push forward with the enrollment of our ongoing Phase 3 trial of APL-2 in PNH, to commence our Phase 3 program of APL-2 in GA, and to present additional data from the Phase 2 POC trial of APL-2 in AIHA and initial data from the Phase 2 POC trial in complement-dependent nephropathies.”
Business Highlights and Upcoming Milestones:
APL-2 in Geographic Atrophy
APL-2 in PNH
APL-2 In Other Indications
Second Quarter 2018 Financial Results:
As of June 30, 2018, Apellis had $253.8 million in cash and cash equivalents, compared to $152.9 million as of March 31, 2018. This includes $131.3 million in net proceeds raised in a public offering of 5.5 million shares of common stock at $25.50 per share in April 2018.
Apellis reported a net loss of $33.3 million for the second quarter of 2018, compared to a net loss of $12.1 million for the second quarter of 2017.
Research and development expenses were $27.5 million in the second quarter of 2018, compared to $10.4 million for the same period in 2017. The increase was primarily due to an increase of $12.1 million in clinical trial costs, an increase of $2.4 million in employee related costs primarily due to the hiring of additional personnel, an increase of $1.9 million in manufacturing expenses, an increase of $0.8 million related to research and development supporting activities and an increase of $0.2 million in pre-clinical study expenses, offset by a decrease of $0.3 million in device development expenses.
General and administrative expenses were $5.9 million in the second quarter of 2018, compared to $1.7 million in the second quarter of 2017. The increase was primarily due to a an increase in employee related costs of $1.6 million, an increase of $0.4 million in director stock option compensation, an increase in office, travel and related costs of $0.5 million, an increase in professional and consulting fees of $1.1 million, an increase in license agreement costs of $0.4 million, and an increase of $0.2 million in insurance costs.
About the PHAROAH Trial
PHAROAH is an ongoing open label Phase 1b safety and efficacy study of 270 mg of APL-2 administered daily by subcutaneous injection as a complementary therapy to patients with PNH who continue to be anemic (Hb <10 g/dL at screening or have a history of at least one transfusion in the previous year) despite treatment with eculizumab. The PHAROAH study was initiated in November 2014 and is being conducted at multiple clinical sites in the United States.
About the PADDOCK Trial
PADDOCK is an ongoing open-label Phase 1b safety and efficacy study of 270 mg of APL-2 administered daily by subcutaneous injection to patients with PNH who have never received eculizumab. The PADDOCK study was initiated in December 2015 and is being conducted at multiple clinical sites outside of the United States.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. For additional information about Apellis and APL-2, please visit http://www.apellis.com.
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether results obtained in preclinical studies and clinical trials, such as the results referenced in this release, will be indicative of results that will be generated in future clinical trials; whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether APL-2 will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of such clinical trials will warrant regulatory submission; whether APL-2 will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if Apellis’ products receive approval, they will be successfully distributed and marketed; whether Apellis’ cash resources will be sufficient to fund the company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 31, 2018, and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
|APELLIS PHARMACEUTICALS, INC.|
|CONSOLIDATED BALANCE SHEETS|
|December 31,||June 30,|
|Cash and cash equivalents||$||175,643,529||$||253,839,540|
|Refundable research and development credit||1,297,361||1,996,996|
|Other current assets||14,823||7,695|
|Total current assets||182,015,306||266,701,518|
|Liabilities and Stockholders' Equity|
|Total current liabilities||6,553,958||10,254,195|
|Term loan facility||19,806,944||20,143,217|
|Promissory note - related party||6,583,402||6,618,150|
|Common stock warrant liability||244,292||250,000|
|Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and
zero shares issued and outstanding at December 31, 2017 and June 30,
|Common stock, $0.0001 par value; 200,000,000 shares authorized
at December 31, 2017 and June 30, 2018 and 50,334,152 shares
issued and outstanding at December 31, 2017 and 56,154,438
shares issued and outstanding at June 30, 2018
|Additional paid in capital||298,201,480||433,880,750|
|Total stockholders' equity||148,942,860||229,552,106|
|Total liabilities and stockholders' equity||$||182,131,456||$||266,817,668|
|APELLIS PHARMACEUTICALS, INC.|
|CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS|
|Three Months Ended||Six Months Ended|
|June 30,||June 30,|
|Research and development||$||10,422,059||$||27,537,619||$||17,653,143||$||44,940,509|
|General and administrative||1,710,344||5,947,823||3,531,753||9,983,079|
|Interest income (expense), net||5,854||184,009||15,966||(82,677||)|
|Other income (expense), net||397||(32,867||)||(7,995||)||(64,341||)|
|Net loss and comprehensive loss||$||(12,126,152||)||$||(33,334,300||)||$||(21,176,925||)||$||(55,070,606||)|
|Net loss per common share, basic and diluted||$||(1.44||)||$||(0.61||)||$||(2.51||)||$||(1.05||)|
|Weighted-average number of common shares used in net|
|loss per common share, basic and diluted||8,428,366||54,691,833||8,428,366||52,534,806|
Investor Contact: Alex Kane email@example.com 212.301.7218 (office) 929.400.2691 (mobile) Media Contact: Tully Nicholas firstname.lastname@example.org 617.482.0042 (office) 860.490.0218 (mobile)